Treatment of W. bancrofti (Wb) in HIV/Wb coinfections in South India

Kawsar R Talaat, Subash Babu, Pradeep Menon, N Kumarasamy, Jabin Sharma, Jeeva Arumugam, Kalaivani Dhakshinamurthy, Ramalingam Srinivasan, S Poongulali, Wenjuan Gu, Michael P Fay, Soumya Swaminathan, Thomas B Nutman, Kawsar R Talaat, Subash Babu, Pradeep Menon, N Kumarasamy, Jabin Sharma, Jeeva Arumugam, Kalaivani Dhakshinamurthy, Ramalingam Srinivasan, S Poongulali, Wenjuan Gu, Michael P Fay, Soumya Swaminathan, Thomas B Nutman

Abstract

Background: The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly acquired coincident infections.

Methodology/principal findings: To assess the influence of pre-existing Wuchereria bancrofti infection on HIV progression, we performed a case-controlled treatment study of HIV positive individuals with (FIL+) or without (FIL-) W. bancrofti infection. Twenty-eight HIV+/FIL+ and 51 matched HIV+/FIL- subjects were treated with a single dose of diethylcarbamazine and albendazole (DEC/Alb) and followed for a year at regular intervals. Sixteen of the HIV+/FIL+ subjects (54%) and 28 of the HIV+/FIL- controls (57%) were on antiretroviral therapy (ART) during the study. Following treatment, no differences were noted in clinical outcomes between the 2 groups. There also was no significant difference between the groups in the HIV viral load at 12 months as a percentage of baseline viral load (HIV+/FIL+ group had on average 0.97 times the response of the HIV+/FIL- group, 95% CI 0.88, 1.07) between the groups. Furthermore, there were no significant differences found in either the change in viral load at 1, 3, or 6 months or in the change in CD4 count at 3, 6, or 12 months between the 2 groups.

Conclusions/significance: We were unable to find a significant effect of W. bancrofti infection or its treatment on HIV clinical course or surrogate markers of HIV disease progression though we recognized that our study was limited by the smaller than predicted sample size and by the use of ART in half of the patients. Treatment of W. bancrofti coinfection in HIV positive subjects (as is usual in mass drug administration campaigns) did not represent an increased risk to the subjects, and should therefore be considered for PLWHA living in W. bancrofti endemic areas.

Trial registration: ClinicalTrials.gov NCT00344279.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Consort diagram.
Fig 1. Consort diagram.
Fig 2. CD4 count and viral load…
Fig 2. CD4 count and viral load comparisons at baseline and 1 year.
Comparison of CD4 and viral load (VL) at baseline (A CD4 [count/dL]), B log VL [log10 RNA Copies]) and at 1 year (C CD4 count, D log VL) between HIV+/FIL+ cases and HIV+/FIL- controls.
Fig 3. HIV viral load by over…
Fig 3. HIV viral load by over time by individual.
HIV VL at baseline and 1 year in HIV+ /FIL+ individuals (A) and HIV+/FIL- individuals (B).
Fig 4. CD4 counts and hemoglobin levels…
Fig 4. CD4 counts and hemoglobin levels over time.
CD4 counts (A and B) and Hemoglobin levels (Hgb) (C and D) at baseline and 1 year between HIV+ /FIL+ individuals (A, C) and HIV+/FIL- individuals (B, D). E. Hemoglobin percent change at 1 year between HIV+/FIL+ and HIV+/FIL- individuals.
Fig 5. A. Wuchereria bancrofti antigen and…
Fig 5. A. Wuchereria bancrofti antigen and antibody levels over time.
Circulating Wuchereria bancrofti antigen levels in HIV+/FIL+ individuals at baseline and 1 year. B. BMA-specific IgG in HIV+/FIL+ subjects at baseline and 1 year. C. Total IgG4 levels in HIV+/FIL+ subjects at baseline and 1 year.

References

    1. Walson JL, Herrin BR, John-Stewart G (2009) Deworming helminth co-infected individuals for delaying HIV disease progression. Cochrane Database Syst Rev: CD006419.
    1. Walson JL, John-Stewart G (2008) Treatment of helminth co-infection in HIV-1 infected individuals in resource-limited settings. Cochrane Database Syst Rev: CD006419.
    1. Sangare LR, Herrin BR, John-Stewart G, Walson JL (2011) Species-specific treatment effects of helminth/HIV-1 co-infection: a systematic review and meta-analysis. Parasitology 138: 1546–1558. 10.1017/S0031182011000357
    1. Wolday D, Mayaan S, Mariam ZG, Berhe N, Seboxa T, et al. (2002) Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr 31: 56–62.
    1. Mulu A, Maier M, Liebert UG (2013) Deworming of intestinal helminths reduces HIV-1 subtype C viremia in chronically co-infected individuals. Int J Infect Dis 17: e897–901. 10.1016/j.ijid.2013.03.022
    1. Elliott AM, Mawa PA, Joseph S, Namujju PB, Kizza M, et al. (2003) Associations between helminth infection and CD4+ T cell count, viral load and cytokine responses in HIV-1-infected Ugandan adults. Trans R Soc Trop Med Hyg 97: 103–108.
    1. Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, et al. (2005) Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults. J Infect Dis 192: 1277–1283.
    1. Webb EL, Kyosiimire-Lugemwa J, Kizito D, Nkurunziza P, Lule S, et al. (2012) The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda. J Acquir Immune Defic Syndr 60: 307–313. 10.1097/QAI.0b013e3182511e42
    1. Lankowski AJ, Tsai AC, Kanyesigye M, Bwana M, Haberer JE, et al. (2014) Empiric Deworming and CD4 Count Recovery in HIV-Infected Ugandans Initiating Antiretroviral Therapy. PLoS Negl Trop Dis 8: e3036 10.1371/journal.pntd.0003036
    1. Kipp W, Bamuhiiga J, Rubaale T (2003) Simulium neavei-transmitted onchocerciasis: HIV infection increases severity of onchocercal skin disease in a small sample of patients. Trans R Soc Trop Med Hyg 97: 310–311.
    1. Tawill SA, Gallin M, Erttmann KD, Kipp W, Bamuhiiga J, et al. (1996) Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients. Trans R Soc Trop Med Hyg 90: 85–89.
    1. Fischer P, Kipp W, Kabwa P, Buttner DW (1995) Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. Am J Trop Med Hyg 53: 171–178.
    1. Nielsen NO, Friis H, Magnussen P, Krarup H, Magesa S, et al. (2007) Co-infection with subclinical HIV and Wuchereria bancrofti, and the role of malaria and hookworms, in adult Tanzanians: infection intensities, CD4/CD8 counts and cytokine responses. Trans R Soc Trop Med Hyg 101: 602–612.
    1. Nielsen NO, Simonsen PE, Dalgaard P, Krarup H, Magnussen P, et al. (2007) Effect of diethylcarbamazine on HIV load, CD4%, and CD4/CD8 ratio in HIV-infected adult Tanzanians with or without lymphatic filariasis: randomized double-blind and placebo-controlled cross-over trial. Am J Trop Med Hyg 77: 507–513.
    1. Nielsen NO, Simonsen PE, Magnussen P, Magesa S, Friis H (2006) Cross-sectional relationship between HIV, lymphatic filariasis and other parasitic infections in adults in coastal northeastern Tanzania. Trans R Soc Trop Med Hyg 100: 543–550.
    1. Talaat KR, Kumarasamy N, Swaminathan S, Gopinath R, Nutman TB (2008) Filarial/human immunodeficiency virus coinfection in urban southern India. Am J Trop Med Hyg 79: 558–560.
    1. National AIDS Control Organisation India DoAc, and Ministry of Health and Family Welfare (2012–2013) Annual Report 2012–2013. In: Control DoA, editor. India: Ministry of Health and Family Welfare, Government of India.
    1. (2011) Annual Report 2010–2011; National AIDS Control Organization. In: Control DoA, editor.
    1. control DoA (2012) Annual Report 2011–2012. In: National AIDS Control Organisation India DoAc, and Ministry of Health and Family Welfare, editor.
    1. Lal RB, Ottesen EA (1988) Enhanced diagnostic specificity in human filariasis by IgG4 antibody assessment. J Infect Dis 158: 1034–1037.
    1. Hothorn T, Hornik K, van de Wiel MA, Zeileis A (2008) Implementing a class of perutation tests: the coin Package. Journal of Statistical Software 28: 1–23.
    1. Dolo H, Coulibaly YI, Dembele B, Konate S, Coulibaly SY, et al. (2012) Filariasis attenuates anemia and proinflammatory responses associated with clinical malaria: a matched prospective study in children and young adults. PLoS Negl Trop Dis 6: e1890 10.1371/journal.pntd.0001890
    1. Blish CA, Sangare L, Herrin BR, Richardson BA, John-Stewart G, et al. (2010) Changes in plasma cytokines after treatment of ascaris lumbricoides infection in individuals with HIV-1 infection. J Infect Dis 201: 1816–1821. 10.1086/652784
    1. Brown M, Kizza M, Watera C, Quigley MA, Rowland S, et al. (2004) Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis 190: 1869–1879.
    1. Mkhize-Kwitshana ZL, Taylor M, Jooste P, Mabaso ML, Walzl G (2011) The influence of different helminth infection phenotypes on immune responses against HIV in co-infected adults in South Africa. BMC Infect Dis 11: 273 10.1186/1471-2334-11-273
    1. Walson JL, Otieno PA, Mbuchi M, Richardson BA, Lohman-Payne B, et al. (2008) Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS 22: 1601–1609. 10.1097/QAD.0b013e32830a502e
    1. Walson JL, Stewart BT, Sangare L, Mbogo LW, Otieno PA, et al. (2010) Prevalence and correlates of helminth co-infection in Kenyan HIV-1 infected adults. PLoS Negl Trop Dis 4: e644 10.1371/journal.pntd.0000644
    1. Ivan E, Crowther NJ, Rucogoza AT, Osuwat LO, Munyazesa E, et al. (2012) Malaria and helminthic co-infection among HIV-positive pregnant women: prevalence and effects of antiretroviral therapy. Acta Trop 124: 179–184. 10.1016/j.actatropica.2012.08.004
    1. Ivan E, Crowther NJ, Mutimura E, Osuwat LO, Janssen S, et al. (2013) Helminthic infections rates and malaria in HIV-infected pregnant women on anti-retroviral therapy in Rwanda. PLoS Negl Trop Dis 7: e2380 10.1371/journal.pntd.0002380
    1. Hosseinipour MC, Napravnik S, Joaki G, Gama S, Mbeye N, et al. (2007) HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi. J Infect Dis 195: 1278–1282.
    1. Walson J, Singa B, Sangare L, Naulikha J, Piper B, et al. (2012) Empiric deworming to delay HIV disease progression in adults with HIV who are ineligible for initiation of antiretroviral treatment (the HEAT study): a multi-site, randomised trial. Lancet Infect Dis 12: 925–932. 10.1016/S1473-3099(12)70207-4

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe